NEW YORK (GenomeWeb) – Locus Biosciences said today that is has acquired EpiBiome's high-throughput bacteriophage discovery platform.

Locus is developing CRISPR-Cas3-engineered precision antibacterial products, and aims to pair EpiBiome's phage isolation and characterization system with its own CRISPR-based synthetic biology platform to develop products to treat antibiotic-resistant bacterial infections and precisely edit the microbiome. Terms of the deal were not disclosed.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

In Science this week: International Wheat Genome Sequencing Consortium publishes the bread wheat cultivar Chinese Spring reference genome, and more.

At his FDA Law Blog, Jeffrey Gibbs discusses FDA's technical assistance for the draft Diagnostic Accuracy and Innovation Act.

The New York Times reports that genetic testing has uncovered unfaithful penguins at a Utah aquarium.

Cancer researcher loses funding under new Wellcome Trust anti-bullying policies, the Guardian reports.